Abstract: A combined low noise amplifier (LNA), mixer, and voltage-controlled oscillator (VCO) circuit (i.e., an LMV cell) includes four dual-gate transistors. These four transistors include series-connected first and second transistors between a ground rail and a first local oscillator signal node and series-connected third and fourth transistors between the ground rail and a second local oscillator signal node. The first and third transistors are LNA components. The second and fourth transistors are cross-coupled VCO components. Front and back gates of the transistors are biased with different combinations of an RF input signal and complementary local oscillator signals generated on the first and second local oscillator nodes.

Abstract: A combined low noise amplifier (LNA), mixer, and voltage-controlled oscillator (VCO) circuit (i.e., an LMV cell) includes four dual-gate transistors. These four transistors include series-connected first and second transistors between a ground rail and a first local oscillator signal node and series-connected third and fourth transistors between the ground rail and a second local oscillator signal node. The first and third transistors are LNA components. The second and fourth transistors are cross-coupled VCO components. Front and back gates of the transistors are biased with different combinations of an RF input signal and complementary local oscillator signals generated on the first and second local oscillator nodes.

Abstract: A component of a communication device includes at least one active element, at least one passive element coupled to the at least one active element, and a first inductor surrounding the at least one active element and the at least one passive element. The first inductor is included in a redistribution structure.

Abstract: A disclosed low noise amplifier (LNA) includes a common-emitter amplifier (CE-A), a common-gate amplifier (CG-A) and various passive devices in CE-A and CG-A. CE-A includes an NPN-type bipolar junction transistor (BJT) with emitter and collector (E/C) regions and a base region between the E/C regions and connected to an input node. CG-A includes P-channel field effect transistor (PFET) with source and drain (S/D) regions, a channel region between the S/D region, and a gate adjacent to the channel region. The drain region of the PFET is connected to an output node. Additionally, a common inductor, collector region of the BJT, and source region of the PFET are connected at an intermediate node. The LNA is implemented on a three-dimensional integrated circuit (3DIC) with the BJT and FET on different chips and with passive devices in back end of the line regions between the BJT and FET.

Abstract: The disclosed subject matter relates generally to an inductor structure integrated in a semiconductor device formed from bonded wafers, in which the semiconductor device has a three-dimensional inductor structure aligned vertically between two integrated circuit (IC) components. The inductor structure has a first metal level and a second metal level, the first metal level being in a different wafer from the second metal level.

Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.

Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention relates to methods and compositions pertaining to conjugates comprising a nucleic acid oligomer conjugated to a glucosamine or a derivative thereof which are useful for inhibiting the transcription of target nucleic acids. The conjugates of the invention exhibit advantageous bioavailability and readily penetrate cell membranes which make them useful for inhibiting translation of target mRNA in vivo.